Zobrazeno 1 - 10
of 659
pro vyhledávání: '"relapsed/refractory multiple myeloma"'
Autor:
Paula Rodriguez-Otero, Thomas Martin
Publikováno v:
Hemato, Vol 5, Iss 2, Pp 171-179 (2024)
The treatment of relapsed and refractory multiple myeloma has improved substantially in the last 5–10 years based on the development and use of several novel classes of drugs and drug combinations. These advances have led to improvements in progres
Externí odkaz:
https://doaj.org/article/f1fcc3e73eef4e409a17047281c1673a
Autor:
Meletios Dimopoulos, Pieter Sonneveld, Salomon Manier, Annette Lam, Tito Roccia, Jordan M. Schecter, Patricia Cost, Lida Pacaud, Abbey Poirier, Gabriel Tremblay, Tommy Lan, Satish Valluri, Shaji Kumar
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-7 (2024)
Abstract Objectives The goal of the research was to assess the quantitative relationship between median progression-free survival (PFS) and median overall survival (OS) specifically among patients with relapsed/refractory multiple myeloma (RRMM) base
Externí odkaz:
https://doaj.org/article/0585a86fa1414c2e9c7c39d6be67cf00
Autor:
Chieh-Lin Jerry Teng, Su-Peng Yeh, Tsai-Yun Chen, Yu-Chin Hung, Yun-Chu Lin, Sin Syue Li, Ming-Chung Wang, Shang-Yi Huang
Publikováno v:
Hematology, Vol 29, Iss 1 (2024)
Background/purpose The treatment landscape of relapsed/refractory multiple myeloma (RRMM) is rapidly evolving in Taiwan. The present study aimed to assess the treatment patterns among RRMM patients in Taiwan.Methods This retrospective, chart review-b
Externí odkaz:
https://doaj.org/article/9593eb70b29941de9fe5b26697691dd5
Publikováno v:
Hematology, Vol 29, Iss 1 (2024)
ABSTRACTVenetoclax is a selective inhibitor of the anti-apoptotic protein B-cell lymphoma 2 (BCL2), as a targeted therapy for multiple myeloma (MM) patients. It was initially approved by the United States Food and Drug Administration for the treatmen
Externí odkaz:
https://doaj.org/article/9c59153d5af146aeb7865719eb56c1fe
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
The introduction of novel agents dramatically improved response and outcomes of multiple myeloma (MM) and led to a sharp decline in the use of allogeneic hematopoietic stem-cell transplantation (allo-HSCT). Thus, recent guidelines do not recommend an
Externí odkaz:
https://doaj.org/article/f3529d442e224ade89fa39162684ba30
Autor:
Niels vanNieuwenhuijzen, Marta Cuenca, Leonie Abbink, Margot Jak, Victor Peperzak, Monique C. Minnema
Publikováno v:
eJHaem, Vol 5, Iss 1, Pp 141-146 (2024)
Abstract Response to daratumumab in patients with relapsed/refractory multiple myeloma is heterogeneous, and a reliable biomarker of response is lacking. We aimed to develop a method that identifies response to daratumumab therapy. Patient‐derived
Externí odkaz:
https://doaj.org/article/95d9a0b5891146baa3b34ed4e6f85dfc
Autor:
Atakan Tekinalp, Ayfer Gedük, Aydan Akdeniz, Esra Terzi Demirsoy, Vildan Gürsoy, Müzeyyen Aslaner Ak, Metin Bağcı, Sema Seçilmiş, Fatma Keklik Karadağ, Ayşe Oruç Uysal, Ali Doğan, Sinan Demircioğlu, Haşim Atakan Erol, Ceyda Aslan, Fahir Özkalemkaş, Şehmus Ertop, Mehmet Dağlı, Mehmet Sinan Dal, Güray Saydam, Mustafa Merter, Cihan Ural, Özcan Çeneli
Publikováno v:
Turkish Journal of Hematology, Vol 40, Iss 4, Pp 242-250 (2023)
Objective: This study aimed to evaluate patients with relapsed/ refractory multiple myeloma (RRMM) who underwent daratumumab (DARA) therapy. Materials and Methods: This multicenter retrospective study included 134 patients who underwent at least two
Externí odkaz:
https://doaj.org/article/4debcdb81b4a4484a3947f563fe04669
Autor:
Darrell White, Gary J. Schiller, Sumit Madan, Suzanne Lentzsch, Evgeni Chubar, Noa Lavi, Dane R. Van Domelen, Ohad S. Bentur, Muhamed Baljevic
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
ObjectiveTo identify the optimal dose of selinexor in combination with pomalidomide and dexamethasone (SPd).MethodsAn analysis of efficacy and safety of 2 once-weekly selinexor regimens (60 mg and 40 mg) with pomalidomide and dexamethasone (SPd-60 an
Externí odkaz:
https://doaj.org/article/faf3645ed4d642638bc528022e510fa6
Autor:
Anna Furlan, Michele Cea, Laura Pavan, Monica Galli, Cristina Clissa, Silvia Mangiacavalli, Anna Maria Cafro, Stefania Girlanda, Francesca Patriarca, Claudia Minotto, Giovanni Bertoldero, Gregorio Barilà, Anna Pascarella, Albana Lico, Rossella Paolini, Nicholas Rabassi, Norbert Pescosta, Marika Porrazzo, Giovanni De Sabbata, Alessandra Pompa, Giulia Bega, Stefania Cavallin, Francesca Guidotti, Magda Marcatti, Maurizio Rupolo, Angelo Belotti, Filippo Gherlinzoni, Renato Zambello
Publikováno v:
Cancer Medicine, Vol 13, Iss 7, Pp n/a-n/a (2024)
Abstract Introduction Ixazomib, lenalidomide, and dexamethasone (IRd) have been approved for the treatment of relapsed/refractory multiple myeloma (RRMM) based on the results of the TOURMALINE‐MM1. Objectives and Methods We conducted a retrospectiv
Externí odkaz:
https://doaj.org/article/0408a307c22a4cd197324662a7fb060f
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Chimeric antigen receptor (CAR) T cell therapy has revolutionized the management of relapsed and refractory myeloma, with excellent outcomes and a tolerable safety profile. High dose chemotherapy with autologous hematopoietic stem cell transplantatio
Externí odkaz:
https://doaj.org/article/f41d1f832b2d465bb373f43bf2b7703c